サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1726197

細胞・遺伝子治療サードパーティロジスティクスの市場規模、シェア、動向分析レポート：タイプ別、製品別、温度範囲別、治療領域別、最終用途別、地域別、セグメント別予測、2025年～2030年

Cell And Gene Therapy Third-Party Logistics Market Size, Share & Trends Analysis Report By Type, By Product, By Temperature Range, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
細胞・遺伝子治療サードパーティロジスティクスの市場規模、シェア、動向分析レポート：タイプ別、製品別、温度範囲別、治療領域別、最終用途別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年04月09日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞・遺伝子治療サードパーティロジスティクス市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の細胞・遺伝子治療サードパーティロジスティクス市場は、2025～2030年にかけてCAGR 11.05％で拡大し、2030年には200億4,000万米ドルに達すると予測されています。

同市場の成長は、主に細胞・遺伝子治療に対する需要の高まりによるもので、正確な取り扱い、厳密な温度管理、メーカー・病院・治療センター間のシームレスな連携が求められます。CGTは患者固有のものであるため、1人の患者の細胞を限られた時間内に収集、輸送、修正、再注入しなければならないです。ロジスティックスに失敗があれば、高価で、救命の可能性のある治療法を失うことになりかねないです。CGTの個別化という性質は、先進的コールドチェーンロジスティクスの必要性を高めており、極低温保管や超低温輸送が標準的な要件となっています。

さらに、CGTの臨床検査と商業認可のパイプラインが増加しているため、ロジスティクスプロバイダはその能力を拡大し、品質を損なうことなく、増加する治療を確実に患者に届けることが求められています。このシフトにより、バイオ医薬品企業はCGTサプライチェーンの複雑性に対応できる専門的な3PLパートナーを求めざるを得なくなり、ロジスティクス効率を最適化しながら厳格な規制要件へのコンプライアンスを確保しています。さらに、規制当局の支援の高まりも市場成長の一因となっています。米国FDA、EMA、その他の世界の規制機関は、効能と安全性を維持するため、CGTの輸送と保管に厳しいガイドラインを課しています。規制遵守のため、ロジスティクスプロバイダは適正流通規範（GDP）や適正製造規範（GMP）を実施する必要があり、これは包装からリアルタイムの追跡に至るまで、サプライチェーン管理のあらゆる側面を管理するものです。コンプライアンスに従わない場合、出荷が拒否され、経済的損失や患者の治療遅延につながる可能性があります。

さらに、パートナーシップや提携、サービスの拡大、製品の発売、パイプライン製品の増加など、市場参入企業によるイニシアティブの高まりが市場成長に寄与しています。例えば、2025年3月、DHLはライフサイエンス向け温度管理ロジスティクスのスペシャリストであるCryoPDPを買収しました。この買収は、先端治療を扱うためのインフラを強化することを目的としています。CryoPDPの超低温保管とリアルタイムモニタリングソリューションに関する専門知識は、バイオ医薬品企業にエンド・ツー・エンドのソリューションを提供するDHLの戦略に合致しています。

細胞・遺伝子治療サードパーティロジスティクス市場レポートハイライト

  • タイプ別では、細胞治療と遺伝子治療の製品パイプラインの増加に伴い、市場各社による研究開発活動が活発化していることから、臨床セグメントが市場を席巻しています。
  • 製品別では、細胞療法が2024年に市場を席巻したが、これは規制当局による承認の増加と商業化への取り組みの拡大によるものです。がん治療におけるCAR-T細胞療法の成功がこの成長に重要な役割を果たし、Novartis、ギリアド・サイエンシズ、ブリストル・マイヤーズ・スクイブなどの企業が普及を牽引しました。
  • 温度範囲別では、超低温や極低温を必要としない遺伝子治療、生物製剤、再生医療製品の需要が増加しているため、2024年には常温保存が最大の市場シェアを占めました。
  • 治療領域別では、がん領域が2024年に市場を席巻したが、これは様々ながん、特に血液がんや固形がんを治療するための先進治療が急速に採用されているためです。
  • 最終用途別では、生物製剤や特殊医薬品の温度管理された保管・輸送への依存度が高いことから、バイオ医薬品企業が2024年に最大の市場シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場動向と展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 技術
  • 価格モデル分析
  • 産業分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 細胞・遺伝子治療サードパーティロジスティクス市場：タイプ別、推定・動向分析

  • セグメントダッシュボード
  • 細胞・遺伝子治療サードパーティロジスティクス市場：タイプ変動分析
  • 細胞・遺伝子治療サードパーティロジスティクスの規模と動向分析（タイプ別、2018～2030年）
  • 臨床
  • 商用

第5章 細胞・遺伝子治療サードパーティロジスティクス市場：製品別、推定・動向分析

  • セグメントダッシュボード
  • 細胞・遺伝子治療サードパーティロジスティクス市場：製品変動分析
  • 細胞・遺伝子治療サードパーティロジスティクスの規模と動向分析（製品別、2018～2030年）
  • 細胞療法
  • 遺伝子治療

第6章 細胞・遺伝子治療サードパーティロジスティクス市場：温度範囲別、推定・動向分析

  • セグメントダッシュボード
  • 細胞・遺伝子治療サードパーティロジスティクス市場：温度範囲変動分析
  • 細胞・遺伝子治療サードパーティロジスティクスの規模と動向分析（温度範囲別、2018～2030年）
  • 常温保存
  • 冷蔵保管
  • 超低温保管
  • 極低温貯蔵

第7章 細胞・遺伝子治療サードパーティロジスティクス市場：治療領域別、推定・動向分析

  • セグメントダッシュボード
  • 細胞・遺伝子治療サードパーティロジスティクス市場：治療領域変動分析
  • 細胞・遺伝子治療サードパーティロジスティクスの規模と動向分析（治療領域別、2018～2030年）
  • 腫瘍学
  • 神経学
  • 心血管疾患
  • 眼科
  • 感染症
  • その他

第8章 細胞・遺伝子治療サードパーティロジスティクス市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • 細胞・遺伝子治療サードパーティロジスティクス市場：最終用途変動分析
  • 細胞・遺伝子治療サードパーティロジスティクスの規模と動向分析（最終用途別、2018～2030年）
  • バイオ医薬品企業
  • CDMO/CMO
  • その他

第9章 地域ビジネス分析

  • 地域ダッシュボード
  • 市場規模と予測と動向分析、2018～2030年
  • 北米
    • 北米の細胞・遺伝子治療サードパーティロジスティクス市場推定・予測、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州の細胞・遺伝子治療サードパーティロジスティクス市場推定・予測、2018～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • アジア太平洋の細胞・遺伝子治療サードパーティロジスティクス市場推定・予測、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの細胞・遺伝子治療サードパーティロジスティクス市場推定・予測、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカの細胞・遺伝子治療サードパーティロジスティクス市場推定・予測、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 企業分類
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • Cencora Corporation
    • Cardinal Health
    • McKesson Corporation
    • EVERSANA
    • Knipper Health
    • Arvato SE
    • DHL
    • FedEx
    • Kuehne+Nagel
    • United Parcel Service of America, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 6 Global Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 7 Global Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 8 Global Cell & Gene Therapy Third-Party Logistics Market, by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Cell & Gene Therapy Third-Party Logistics Market, by Country, 2018 - 2030 (USD Million)
  • Table 10 North America Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 North America Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 North America Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 13 North America Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 14 North America Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 15 U.S. Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 U.S. Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 17 U.S. Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 18 U.S. Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 19 U.S. Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Canada Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 22 Canada Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 23 Canada Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24 Canada Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Mexico Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 26 Mexico Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Mexico Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 28 Mexico Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 29 Mexico Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Europe Cell & Gene Therapy Third-Party Logistics Market, by Country, 2018 - 2030 (USD Million)
  • Table 31 Europe Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 32 Europe Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Europe Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 34 Europe Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 35 Europe Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 UK Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 UK Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 38 UK Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 39 UK Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 40 UK Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Germany Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Germany Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 43 Germany Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 44 Germany Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 45 Germany Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 46 France Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 France Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 France Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 49 France Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 50 France Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Italy Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Italy Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 53 Italy Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 54 Italy Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 55 Italy Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Spain Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 Spain Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 58 Spain Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 59 Spain Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 60 Spain Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Denmark Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Denmark Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 63 Denmark Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 64 Denmark Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 65 Denmark Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Sweden Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Sweden Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 68 Sweden Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 69 Sweden Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 70 Sweden Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 71 Norway Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 72 Norway Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 73 Norway Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 74 Norway Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 75 Norway Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, by Country, 2018 - 2030 (USD Million)
  • Table 77 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 78 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 79 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 80 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 81 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 82 Japan Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Japan Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 84 Japan Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 85 Japan Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 86 Japan Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 China Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 China Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 89 China Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 90 China Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 91 China Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 India Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 India Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 94 India Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 95 India Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 96 India Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 97 Australia Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 98 Australia Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 99 Australia Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 100 Australia Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 101 Australia Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 102 South Korea Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 103 South Korea Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 104 South Korea Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 105 South Korea Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 106 South Korea Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 107 Thailand Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 108 Thailand Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 109 Thailand Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 110 Thailand Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 111 Thailand Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 112 Latin America Cell & Gene Therapy Third-Party Logistics Market, by Country, 2018 - 2030 (USD Million)
  • Table 113 Latin America Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 114 Latin America Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 115 Latin America Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 116 Latin America Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 117 Latin America Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 118 Brazil Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 119 Brazil Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 120 Brazil Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 121 Brazil Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 122 Brazil Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 123 Argentina Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 124 Argentina Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 125 Argentina Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 126 Argentina Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 127 Argentina Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 128 MEA Cell & Gene Therapy Third-Party Logistics Market, by Country, 2018 - 2030 (USD Million)
  • Table 129 MEA Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 130 MEA Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 131 MEA Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 132 MEA Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 133 MEA Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 134 South Africa Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 135 South Africa Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 136 South Africa Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 137 South Africa Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 138 South Africa Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 143 Saudi Arabia Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 144 UAE Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 145 UAE Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 146 UAE Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 147 UAE Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 148 UAE Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 149 Kuwait Cell & Gene Therapy Third-Party Logistics Market, by Type, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Cell & Gene Therapy Third-Party Logistics Market, by Product, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Cell & Gene Therapy Third-Party Logistics Market, by Temperature Range, 2018 - 2030 (USD Million)
  • Table 152 Kuwait Cell & Gene Therapy Third-Party Logistics Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 153 Kuwait Cell & Gene Therapy Third-Party Logistics Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Cell & Gene Therapy Third-Party Logistics Market Segmentation
  • Fig. 7 Market Snapshot, 2024
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Global Cell & Gene Therapy Third-Party Logistics Market: Type Key Takeaways
  • Fig. 14 Global Cell & Gene Therapy Third-Party Logistics Market: Type Movement Analysis
  • Fig. 15 Global Cell & Gene Therapy Third-Party Logistics Market, for Clinical, 2018 - 2030 (USD Million)
  • Fig. 16 Global Cell & Gene Therapy Third-Party Logistics Market, for Commercial, 2018 - 2030 (USD Million)
  • Fig. 17 Global Cell & Gene Therapy Third-Party Logistics Market: Product Key Takeaways
  • Fig. 18 Global Cell & Gene Therapy Third-Party Logistics Market: Product Movement Analysis
  • Fig. 19 Global Cell & Gene Therapy Third-Party Logistics Market, for Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 20 Global Cell & Gene Therapy Third-Party Logistics Market, for Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 21 Global Cell & Gene Therapy Third-Party Logistics Market: Temperature Range Key Takeaways
  • Fig. 22 Global Cell & Gene Therapy Third-Party Logistics Market, Temperature Range Movement Analysis
  • Fig. 23 Global Cell & Gene Therapy Third-Party Logistics Market, for Ambient Storage, 2018 - 2030 (USD Million)
  • Fig. 24 Global Cell & Gene Therapy Third-Party Logistics Market, for Refrigerated Storage, 2018 - 2030 (USD Million)
  • Fig. 25 Global Cell & Gene Therapy Third-Party Logistics Market, for Ultra-Low Temperature Storage, 2018 - 2030 (USD Million)
  • Fig. 26 Global Cell & Gene Therapy Third-Party Logistics Market, for Cryogenic Storage, 2018 - 2030 (USD Million)
  • Fig. 27 Global Cell & Gene Therapy Third-Party Logistics Market: Therapeutic Area Key Takeaways
  • Fig. 28 Global Cell & Gene Therapy Third-Party Logistics Market, Therapeutic Area Movement Analysis
  • Fig. 29 Global Cell & Gene Therapy Third-Party Logistics Market, Oncology, 2018 - 2030 (USD Million)
  • Fig. 30 Global Cell & Gene Therapy Third-Party Logistics Market, for Neurology, 2018 - 2030 (USD Million)
  • Fig. 31 Global Cell & Gene Therapy Third-Party Logistics Market, for cardiovascular diseases, 2018 - 2030 (USD Million)
  • Fig. 32 Global Cell & Gene Therapy Third-Party Logistics Market, for Ophthalmology, 2018 - 2030 (USD Million)
  • Fig. 33 Global Cell & Gene Therapy Third-Party Logistics Market, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 34 Global Cell & Gene Therapy Third-Party Logistics Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 35 Global Cell & Gene Therapy Third-Party Logistics Market: End Use Key Takeaways
  • Fig. 36 Global Cell & Gene Therapy Third-Party Logistics Market, End Use Movement Analysis
  • Fig. 37 Global Cell & Gene Therapy Third-Party Logistics Market, for Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 38 Global Cell & Gene Therapy Third-Party Logistics Market, for CDMOs/CMOs, 2018 - 2030 (USD Million)
  • Fig. 39 Global Cell & Gene Therapy Third-Party Logistics Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Regional Marketplace: Key Takeaways
  • Fig. 41 Regional Outlook, 2024 & 2030
  • Fig. 42 North America Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 47 Germany Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 48 UK Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 49 France Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 57 China Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 58 India Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East and Africa Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait Cell & Gene Therapy Third-Party Logistics Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-550-5

Cell & Gene Therapy Third-Party Logistics Market Growth & Trends:

The global cell and gene therapy third-party logistics market is expected to reach USD 20.04 billion by 2030, expanding at a CAGR of 11.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is mainly due to rising demand for cell and gene therapies, which require precise handling, strict temperature controls, and seamless coordination between manufacturers, hospitals, and treatment centers. CGTs are patient-specific, which signifies that a single patient's cells must be collected, transported, modified, and reinfused within tight timelines. Any failure in logistics can result in the loss of an expensive, potentially life-saving therapy. The personalized nature of CGTs has increased the need for advanced cold chain logistics, with cryogenic storage and ultra-low temperature transportation becoming standard requirements.

In addition, the growing pipeline of CGT clinical trials and commercial approvals encourages logistics providers to scale their capabilities, ensuring that the increasing volume of therapies reaches patients without compromising quality. This shift is compelling biopharmaceutical companies to seek specialized 3PL partners that can handle the complexities of CGT supply chains, ensuring compliance with strict regulatory requirements while optimizing distribution efficiency. Moreover, the growing regulatory support is also one of the factors contributing to market growth. The U.S. FDA, EMA, and other global regulatory bodies impose stringent guidelines on the transportation and storage of CGTs to maintain their potency and safety. Regulatory compliance requires logistics providers to implement Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP) standards, which govern every aspect of supply chain management, from packaging to real-time tracking. Failure to comply can result in rejected shipments, financial losses, and treatment delays for patients.

Furthermore, growing initiatives by the market players, such as partnerships and collaborations, service expansion, product launches, and increasing pipeline products, contribute to market growth. For instance, in March 2025, DHL acquired CryoPDP, a specialist in temperature-controlled logistics for life sciences. The acquisition aims to strengthen the infrastructure for handling advanced therapies. CryoPDP's expertise in ultra-cold storage and real-time monitoring solutions aligns with DHL's strategy, providing end-to-end solutions for biopharma companies.

Cell And Gene Therapy Third-Party Logistics Market Report Highlights:

  • Based on type, the clinical segment dominated the market due to the increasing number of research and development activities by the market players coupled with the growing number of cell and gene therapies product pipelines.
  • Based on the product, cell therapies dominated the market in 2024 due to increasing regulatory approvals and expanding commercialization efforts. The success of CAR-T cell therapies for cancer treatment played a crucial role in this growth, with companies like Novartis, Gilead Sciences, and Bristol Myers Squibb driving widespread adoption.
  • Based on temperature range, ambient storage held the largest market share in 2024due to the increasing demand for gene therapies, biologics, and regenerative medicine products that do not require ultra-low or cryogenic temperatures.
  • Based on the therapeutic area, the oncology segment dominated the market in 2024due to the rapid adoption of advanced therapies for treating various cancers, particularly hematologic and solid tumors.
  • Based on end use, biopharmaceutical companies held the largest market share in 2024due to their high reliance on temperature-controlled storage and transportation for biologics and specialty drugs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Information Analysis
    • 1.4.2. Market Formulation & Data Visualization
    • 1.4.3. Data Validation & Publishing
  • 1.5. Model Details
    • 1.5.1. Commodity Flow Analysis (Model 1)
    • 1.5.2. Top Down Market Estimation (Model 2)
    • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
    • 1.5.4. Multivariate Analysis (Model 4)
  • 1.6. List of Secondary Sources
  • 1.7. List of Abbreviations
  • 1.8. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Technology Landscape
  • 3.5. Pricing Model Analysis
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Cell & Gene Therapy Third-Party Logistics Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cell & Gene Therapy Third-Party Logistics Market; Type Movement Analysis
  • 4.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Clinical
    • 4.4.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Commercial
    • 4.5.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cell & Gene Therapy Third-Party Logistics Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cell & Gene Therapy Third-Party Logistics Market; Product Movement Analysis
  • 5.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.4. Cell Therapies
    • 5.4.1. Cell therapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Gene Therapies
    • 5.5.1. Gene therapies market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cell & Gene Therapy Third-Party Logistics Market: Temperature Range Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cell & Gene Therapy Third-Party Logistics Market; Temperature Range Movement Analysis
  • 6.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Temperature Range, 2018 to 2030 (USD Million)
  • 6.4. Ambient Storage
    • 6.4.1. Ambient storage market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Refrigerated Storage
    • 6.5.1. Refrigerated storage market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Ultra-Low Temperature Storage
    • 6.6.1. Ultra-Low temperature storage market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Cryogenic Storage
    • 6.7.1. Cryogenic storage market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cell & Gene Therapy Third-Party Logistics Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Cell & Gene Therapy Third-Party Logistics Market; Therapeutic Area Movement Analysis
  • 7.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Neurology
    • 7.5.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Cardiovascular Diseases
    • 7.6.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Ophthalmology
    • 7.7.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Infectious Diseases
    • 7.8.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Cell & Gene Therapy Third-Party Logistics Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Cell & Gene Therapy Third-Party Logistics Market; End Use Movement Analysis
  • 8.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Biopharmaceutical Companies
    • 8.4.1. Biopharmaceutical Companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. CDMOs/CMOs
    • 8.5.1. CDMOs/CMOs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Regional Business Analysis

  • 9.1. Regional Dashboard
  • 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 9.3. North America
    • 9.3.1. North America cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Competitive scenario
      • 9.3.2.3. Regulatory framework
      • 9.3.2.4. U.S. cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Competitive scenario
      • 9.3.3.3. Regulatory framework
      • 9.3.3.4. Canada cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamics
      • 9.3.4.2. Competitive scenario
      • 9.3.4.3. Regulatory framework
      • 9.3.4.4. Mexico cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Competitive scenario
      • 9.4.2.3. Regulatory framework
      • 9.4.2.4. Germany cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.3. UK
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Competitive scenario
      • 9.4.3.3. Regulatory framework
      • 9.4.3.4. UK cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Competitive scenario
      • 9.4.4.3. Regulatory framework
      • 9.4.4.4. France cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Competitive scenario
      • 9.4.5.3. Regulatory framework
      • 9.4.5.4. Italy cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Competitive scenario
      • 9.4.6.3. Regulatory framework
      • 9.4.6.4. Spain cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Competitive scenario
      • 9.4.7.3. Regulatory framework
      • 9.4.7.4. Denmark cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Competitive scenario
      • 9.4.8.3. Regulatory framework
      • 9.4.8.4. Sweden cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key country dynamics
      • 9.4.9.2. Competitive scenario
      • 9.4.9.3. Regulatory framework
      • 9.4.9.4. Norway cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Competitive scenario
      • 9.5.2.3. Regulatory framework
      • 9.5.2.4. Japan cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Competitive scenario
      • 9.5.3.3. Regulatory framework
      • 9.5.3.4. China cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Competitive scenario
      • 9.5.4.3. Regulatory framework
      • 9.5.4.4. India cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Competitive scenario
      • 9.5.5.3. Regulatory framework
      • 9.5.5.4. South Korea cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.6. Australia
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Competitive scenario
      • 9.5.6.3. Regulatory framework
      • 9.5.6.4. Australia cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.7. Thailand
      • 9.5.7.1. Key country dynamics
      • 9.5.7.2. Competitive scenario
      • 9.5.7.3. Regulatory framework
      • 9.5.7.4. Thailand cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Competitive scenario
      • 9.6.2.3. Regulatory framework
      • 9.6.2.4. Brazil cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Competitive scenario
      • 9.6.3.3. Regulatory framework
      • 9.6.3.4. Argentina cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Competitive scenario
      • 9.7.2.3. Regulatory framework
      • 9.7.2.4. South Africa cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Competitive scenario
      • 9.7.3.3. Regulatory framework
      • 9.7.3.4. Saudi Arabia cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Competitive scenario
      • 9.7.4.3. Regulatory framework
      • 9.7.4.4. UAE cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Competitive scenario
      • 9.7.5.3. Regulatory framework
      • 9.7.5.4. Kuwait cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Company Market Share/Assessment Analysis, 2024
  • 10.3. Company Profiles
    • 10.3.1. Cencora Corporation
      • 10.3.1.1. Company overview
      • 10.3.1.2. Financial performance
      • 10.3.1.3. Service benchmarking
      • 10.3.1.4. Strategic initiatives
    • 10.3.2. Cardinal Health
      • 10.3.2.1. Company overview
      • 10.3.2.2. Financial performance
      • 10.3.2.3. Service benchmarking
      • 10.3.2.4. Strategic initiatives
    • 10.3.3. McKesson Corporation
      • 10.3.3.1. Company overview
      • 10.3.3.2. Financial performance
      • 10.3.3.3. Service benchmarking
      • 10.3.3.4. Strategic initiatives
    • 10.3.4. EVERSANA
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Service benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Knipper Health
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Service benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Arvato SE
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Service benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. DHL
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Service benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. FedEx
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Service benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Kuehne+Nagel
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Service benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. United Parcel Service of America, Inc.
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Service benchmarking
      • 10.3.10.4. Strategic initiatives